O.E. SUPRUN², A.E. BAGRIY¹, E.S. MYKHAILICHENKO¹, E.A. ANDREEVA², E.A. PYLAEVA¹, E.V. SUPRUN²

 ¹M. Gorky Donetsk State Medical University, Donetsk, Donetsk Peoples’s Republic

²Railway Clinical Hospital of Donetsk station, Donetsk, Donetsk People’s Republic

Contact details:

Mykhailichenko E.S. — Ph. D. (Medicine), Assistant Professor of the Department of Internal Diseases No. 2

Address: 16 prospekt Ilyicha, Donetsk, Donetsk People’s Republic, Russian Federation, 283003, tel.: +7-949-470-68-08, e-mail: klassiki@inbox.ru

Among the disorders associated with type 2 diabetes mellitus, intestinal functional changes (irritable bowel syndrome — IBS) are an insufficiently studied problem.

The purpose — a prospective study of the efficacy and safety of various hypoglycemic treatment regimens in patients with IBS and type 2 diabetes mellitus.

Material and methods

The study included 107 patients aged 48.9 ± 9.4 years with type 2 diabetes mellitus and clinical manifestations of IBS, who were divided into 4 groups depending on the prescribed hypoglycemic therapy: patients of group A received metformin, group B — a combination of metformin with saxagliptin, group C — a combination of metformin with liraglutide or exenatide, group D — combination of metformin with dapagliflozin. The duration of the study was not less than 5 months.

Results. Treatment in all groups resulted in a significant decrease in the average values of HbA1c, fructosamine, insulin, C-peptide and the HOMA-IR index, an increase in the values of the NOMA-B index, p < 0.05. A more significant absolute and relative decrease in the levels of HbA1c, insulin and HOMA-IR index was observed in groups C and D in comparison with groups A and B. The use of various classes of hypoglycemic drugs in people with IBS and type 2 diabetes mellitus was characterized by satisfactory tolerability and was associated with a significant decrease in clinical manifestations of constipation, diarrhea, abdominal pain, gastroesophageal reflux, and a positive effect on glycemic levels. The criteria for predicting the effectiveness and safety of hypoglycemic treatment in patients with a combination of IBS and type 2 diabetes mellitus were the diabetes duration < 7 years, the values of HOMA-IR <5 and NOMA-B ³ 60, the absence of smoking, the uric acid concentration in blood < 350 mmol/ l, the absence of hypothyroidism and the choice of dapagliflozin as a component of hypoglycemic therapy.

Key words: diabetes mellitus, irritable bowel syndrome, hypoglycemic therapy, metformin, dapagliflozin, saxagliptin, liraglutide, exenatide.

REFERENCES

1. Dedov I.I., Shestakova M.V., Mayorov A.Yu. et al. Type 2 diabetes mellitus in adults. Clinical recommendations. Sakharnyy diabet, 2020, vol. 23, no. S2, pp. 4–102 (in Russ.).
2. American Diabetes Association. ADA Standards of Medical Care in Diabetes- 2023. Diabetes Care, 2023, vol. 46 (1), pp. S1–S291.
3. Ignatenko G.A., Bagriy A.E., Oprishchenko A.A. Sakharnyy diabet: rukovodstvo dlya vrachey [Diabetes mellitus: a guide for doctors]. Donetsk: RB Pozitiv, 2022. 640 p.
4. Osipenko M.F., Vorontsova E.S., Zhuk E.A. et al. Gastroenterological symptoms in type 2 diabetes. Eksperimental’naya i klinicheskaya gastroenterologiya, 2015, vol. 115, no. 3, pp. 84–89 (in Russ.).
5. Runova A.A., Zhulina L.I., Kalinnikova L.A. et al. Features of the treatment of irritable bowel syndrome in patients with type 2 diabetes. Eksperimental’naya i klinicheskaya gastroenterologiya, 2015, vol. 117, no. 5, pp. 105–106 (in Russ.).
6. Maev I.V., Samsonov A.A., Dicheva D.T. et al. Clinical and functional disorders of the upper digestive tract in patients with type 2 diabetes. Effektivnaya farmakoterapiya, 2019, vol. 15, no. 18, pp. 10–14 (in Russ.).
7. Vasant D.H., Paine P.A., Black C.J. et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut, 2021, vol. 79, pp. 1–27. DOI: 10.1136/gutjnl-2021-324598
8. Bagriy A.E., Shchukina E.V., Mikhaylichenko E.S. et al. Modern drug approaches to glycemic control in patients with diabetes mellitus types 1 and 2. Farmateka, 2021, vol. 28, no. 4, pp. 74–95 (in Russ.). DOI: 10.18565/pharmateca.2021.4.69-75
9. Abrahami D., Douros A., Yin H. et al. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. British Medical Journal, 2018, vol. 360, pp. e119–e121. DOI: 10.1136/bmj.k872
10. Karhus M.L., Bronden A., Roder M.E. et al. Remission of bile acid malabsorption symptoms following treatment with the glucagon-like peptide 1 receptor agonist liraglutide. Gastroenterology, 2019, vol. 157, pp. 569–571. DOI: 10.1053/j.gastro.2019.04.002
11. Yazbeck R., Howarth G.S., Geier M.S. Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in mice. Front Biosci, 2008, vol. 13, pp. 6850–6858. DOI: 10.2741/3193
12. Ivashkin I.T., Maev I.V., Shelygin Yu.A. et al. Diagnosis and treatment of irritable bowel syndrome (Clinical recommendations of the Russian Gastroenterological Association and the Association of Coloproctologists of Russia). Ros. zhurn. gastroenterol., gepatol., kolonoproktol, 2021, vol. 31, no. 5, pp. 76–93 (in Russ.). DOI: 10.22416/1382-4376-2021-31-5-74-95
13. Ford A.C., Moayyedi P., Chey W.D. et al. American College of Gastroenterology monograph on management of irritable bowel syndrome. Am. J. Gastroenterol, 2018, vol. 114 (1), pp. 21–39. DOI: 10.1038/s41395-018-0084-x
14. Bajaj A. The variable portability — irritable bowel syndrome. EC Gastroenterology and Digestive system, 2020, vol. 7 (2), pp. 1–9.
15. Ford A.C., Lacy B.E., Talley N.J. Irritable bowel syndrome. N Engl J Med, 2017, vol. 376, pp. 2566–2578. DOI: 10.1056/NEJMra1607547
16. Shklyaev A.E., Pantyukhina A.S., Benderskaya E.Yu. Quality of life of patients with irritable bowel syndrome during treatment. Zdorov’e i obrazovanie, 2017, vol. 19, no. 10, pp. 143–145 (in Russ.).
17. Petri A., Sabin K. Naglyadnaya meditsinskaya statistika [Visual medical statistics]. Moscow: GEOTAR-Media, 2021. 224 p.
18. Perry P., Kapur N., Barrett T.A. DPP-4 as a novel biomarker for inflammatory bowel disease: is it ready for clinical use? Inflamm. Bowel Dis, 2020, vol. 26, pp. 1720–1721. DOI: 10.1093/ibd/izz320
19. Li G., Crjwley M.J., Tang H. et al. Dipeptidyl peptidase inhibitors and risk of inflammatory bowel disease among patients with type 2 diabetes: a meta-analysis of randomizes controlled trials. Diabetes Care, 2019, vol. 42, pp. e119–e121. DOI: 10.2337/dc18-1578
20. Shestakova M.V., Vikulova O.K., Zheleznyakova A.V. et al. Epidemiology of diabetes mellitus in the Russian Federation: what has changed over the last decade? Terapevticheskiy arkhiv, 2019, vol. 91, no. 10, pp. 4–13 (in Russ.).